LSUHSC Cardiovascular Center and Novo Biosciences Receive $1.

5 million NIH Grant to

Study Myocardial Regeneration
New Orleans, LA (August 28, 2017) – LSU Health Cardiovascular Center of Excellence received a
grant award from the National Heart, Lung and Blood Institute to research the development, a novel
agent, MSI-1346, for therapeutic stimulation of heart regeneration following acute myocardial infarction
and heart failure. The grant will provide more than $500,000 in funding over two years to LSUHSC-New
Orleans along with Novo Biosciences in Bar Harbor, Maine in ongoing research for the project.

In randomized experimental and data analysis protocols, MSI-1346 has been shown to regenerate heart,
connective, nerve, skin, bone and vascular tissues in adult zebrafish. MSI-1346 also reverses genetically
induced cardiac scar formation. In addition to researching advancements to improve heart function, MSI-
1346 has already shown positive results in clinical trial patients with obesity and type-2 diabetes.

This award will further test a drug previously shown to be safe in humans that could be a critical step to
eventually testing heart attack patients in the future. Both LSUHSC Cardiovascular Center and Novo
Biosciences are confident that the grant will only begin to open more opportunities into potentially
offering a new method to treating heart disease, the world’ leading cause of mortality and morbidity in
humans.

This research will be led by Cardiovascular Center of Excellence Director David Lefer, Ph.D., and Dr. Traci
Goodchild, Ph.D. who is the Director of Cardiovascular Translational Research at LSU Health New Orleans.
The translational core laboratory provides state-of-the-art work spaces include physiology laboratories,
surgical suites, biochemistry and molecular laboratories and core laboratories, which will further testing
on the efficacy of MSI-1346, the crucial step in potential clinical trials.

“We are very excited to collaborate with the team at Novo Biosciences on this very promising therapeutic
agent for the treatment of heart failure,” said Lefer. “If our studies are successful, MSI-1346 could be very
rapidly translated to the clinic and impact the lives of heart failure patients.”

_____________________________________________________________________________________
LSU Health Sciences Center New Orleans educates Louisiana’s health care professionals. The state’s health
sciences university leader, LSU Health New Orleans includes a School of Medicine, the state’s only School of
Dentistry, Louisiana’s only public School of Public Health, and Schools of Allied Health Professions, Nursing, and
Graduate Studies. LSUHSC faculty take care of patients in public and private hospitals and clinics throughout the
region. In the vanguard of biosciences research in a number of areas in a worldwide arena, the LSUHSC research
enterprise generates jobs and enormous economic impact. LSUHSC faculty have made lifesaving discoveries and
continue to work to prevent, advance treatment, or cure disease. To learn more,
visit http://www.lsuhsc.edu, http://www.twitter.com/LSUHealthNO or http://www.facebook.com/LSUHSC.

Novo Biosciences based of Bar Harbor, Maine is a regenerative medicine company developing small molecule
therapies that reactivate and stimulate innate healing abilities in humans and animals.
http://novobiosciences.com/

“Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the
National Institutes of Health under Award Number R44HL139161. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the National Institutes of Health.”